摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-羟基-4-(5-嘧啶-2-基吡啶-2-基)环己酮 | 857651-06-0

中文名称
4-羟基-4-(5-嘧啶-2-基吡啶-2-基)环己酮
中文别名
PF-04136309中间体
英文名称
4-hydroxy-4-[5-(pyrimidin-2-yl)pyridin-2-yl]cyclohexan-1-one
英文别名
4-Hydroxy-4-[5-(2-pyrimidinyl)-2-pyridyl]cyclohexanone;4-hydroxy-4-(5-pyrimidin-2-ylpyridin-2-yl)cyclohexan-1-one
4-羟基-4-(5-嘧啶-2-基吡啶-2-基)环己酮化学式
CAS
857651-06-0
化学式
C15H15N3O2
mdl
——
分子量
269.303
InChiKey
SCFKTBHPKNQOBT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0
  • 重原子数:
    20
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    76
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-羟基-4-(5-嘧啶-2-基吡啶-2-基)环己酮吡啶 、 palladium 10% on activated carbon 、 氢气盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺三乙胺 作用下, 以 甲醇 为溶剂, 反应 25.0h, 生成 (S)-3-((29-((2,4-dinitrophenyl)amino)-3,6,9,12,15,18,21,24,27-nonaoxanonacosyl)oxy)-N-(2-(3-((4-hydroxy-4-(5-(pyrimidin-2-yl)pyridin-2-yl)cyclohexyl)amino)pyrrolidin-1-yl)-2-oxoethyl)-5-(trifluoromethyl)benzamide
    参考文献:
    名称:
    [EN] NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES
    [FR] MOLÉCULES HÉTÉROBIVALENTES NON PEPTIDIQUES PERMETTANT LE TRAITEMENT DE MALADIES INFLAMMATOIRES
    摘要:
    本发明涉及能够同时结合表面靶蛋白和内源或外源人类抗体蛋白并诱导免疫效应功能的非肽类、异二价分子(HBM)。更具体地,本发明涉及能够结合趋化因子受体并诱导受体阳性病原细胞亚群在受试者中的减少的药剂,用于治疗和/或预防癌症、炎症、自身免疫和过敏性疾病。
    公开号:
    WO2018134731A1
  • 作为产物:
    参考文献:
    名称:
    Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist
    摘要:
    We report the discovery of a new (S)-3-aminopyrrolidine series of CCR2 antagonists. Structure-activity relationship studies on this new series led to the identification of 17 (INCB8761/PF-4136309) that exhibited potent CCR2 antagonistic activity, high selectivity, weak hERG activity, and an excellent in vitro and in vivo ADMET profile. INCB8761/PF-4136309 has entered human clinical trials.
    DOI:
    10.1021/ml200199c
  • 作为试剂:
    描述:
    4-羟基-4-(5-嘧啶-2-基吡啶-2-基)环己酮 、 N-[2-(3-aminopyrrolidin-1-yl)-2-oxoethyl]-3-(trifluoromethyl)benzamide;hydrochloride 在 4-羟基-4-(5-嘧啶-2-基吡啶-2-基)环己酮 作用下, 以66的产率得到PF-4136309
    参考文献:
    名称:
    ACS Med. Chem. Lett. 2011, 2, 913-918
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • 3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors
    申请人:Xue Chu-Biao
    公开号:US20070149532A1
    公开(公告)日:2007-06-28
    The present invention is directed to compounds of Formula I: I which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
    本发明涉及化合物I的化合物:I,这些化合物是趋化因子受体的调节剂。本发明的化合物及其组合物在治疗与趋化因子受体表达和/或活性相关的疾病方面是有用的。
  • 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
    申请人:Xue Chu-Biao
    公开号:US20050192302A1
    公开(公告)日:2005-09-01
    The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula I: (wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.
    本发明涉及公式I的3-环烷胺基吡咯烷衍生物:(其中R1、R2、R3、R4、R5、R6、R7、X、Y和Z如本文所定义),这些衍生物可用作化学因子受体活性的调节剂。特别是,这些化合物可用作化学因子受体的调节剂,更具体地作为CCR2和/或CCR5受体的调节剂。本发明的化合物和组合物可能结合化学因子受体,例如CCR2和/或CCR5化学因子受体,并且可用于治疗与化学因子(例如CCR2和/或CCR5)活性相关的疾病,如动脉粥样硬化、再狭窄、狼疮、器官移植排斥和类风湿性关节炎。
  • Thiosemicarbazones as anti-virals and immunopotentiators
    申请人:Barsanti Paul A.
    公开号:US20090285849A1
    公开(公告)日:2009-11-19
    Novel immune potentiators, novel vaccine adjuvants, novel compounds and pharmaceutical compositions, as well as novel methods for treating viral infections, including HCV, by administering the compounds and compositions, and novel methods for modulating the immune response by administering the compounds and/or compositions.
    新型免疫增强剂、新型疫苗佐剂、新型化合物和制药组合物,以及通过给予这些化合物和组合物治疗病毒感染的新方法,包括HCV,以及通过给予这些化合物和/或组合物调节免疫反应的新方法。
  • 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS
    申请人:Xue Chu-Biao
    公开号:US20090286792A1
    公开(公告)日:2009-11-19
    The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula I: (wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.
    本发明涉及式I的3-环烷基吡咯烷衍生物(其中R1,R2,R3,R4,R5,R6,R7,X,Y和Z如本文所定义),它们可用作趋化因子受体活性的调节剂。特别地,这些化合物可用作趋化因子受体的调节剂,更具体地,可用作CCR2和/或CCR5受体的调节剂。本发明的化合物和组合物可以结合趋化因子受体,例如CCR2和/或CCR5趋化因子受体,并可用于治疗与趋化因子,例如CCR2和/或CCR5活性相关的疾病,如动脉硬化,再狭窄,狼疮,器官移植排斥和类风湿性关节炎。
  • 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS
    申请人:Xue Chu-Biao
    公开号:US20100203039A1
    公开(公告)日:2010-08-12
    The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
    本发明涉及化合物I的调节剂,其是趋化因子受体的调节剂。本发明的化合物及其组合物在治疗与趋化因子受体表达和/或活性相关的疾病方面是有用的。
查看更多